PROF - Bathi resik saben saham (EPS TTM) Profound Medical Corporation

Net income per share over the last four quarters correlates with revenues from services and the sale of ultrasound robots for prostate therapy, where -0.93 records the value of this parameter for Profound Medical Corp. (PROF). Profit growth is driven by demand for high-margin consumables. The trend depends on insurance payouts and the control of expansion costs during the implementation of TULSA-PRO systems.

For Profound Medical Corp. (PROF), trailing twelve-month (TTM) net income per share serves as a metric for the monetization efficiency of TULSA-PRO robotic therapy, allocating the final financial result among all shareholders. By analyzing the TTM net income per share, an investor can gauge the company's actual pace toward profitability amid expanding insurance coverage for procedures and the scaling of non-invasive treatment.